Diatech Pharmacogenetics http://diatechpharmacogenetics.com/rss.php?lng=en Diatech Pharmacogenetics : News en New Products Posted to GenomeWeb This Week: Diatech Pharmacogenetics, Helix, Helomics, and NuGen Technologies http://diatechpharmacogenetics.com/en/903/new-products-posted-to-genomeweb-this-week-diatech-pharmacogenetics-helix-helomics-and-nugen-technologies Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/903/new-products-posted-to-genomeweb-this-week-diatech-pharmacogenetics-helix-helomics-and-nugen-technologies http://diatechpharmacogenetics.com/en/903/new-products-posted-to-genomeweb-this-week-diatech-pharmacogenetics-helix-helomics-and-nugen-technologies 21.04.2017 Diatech Pharmacogenetics EasyPGX kits, Helix cfDNA kit

Diatech Pharmacogenetics, an Italian molecular diagnostics firm, has launched a line of PCR-based oncology kits and a kit to detect circulating free DNA. The easyPGX line of PCR kits includes assays for the detection of KRAS, NRAS, BRAF, EGFR, involved in many solid tumors, of DPYD and UGT1A1 variants associated with toxicity upon Fluoropyrimidines and Irinotecan treatment respectively, and a Thyroid panel. The sensitivity of the assays is as low as 0.5 percent, the firm said, and the starting material can be DNA extracted from fresh, frozen, and formalin-fixed paraffin-embedded tissues and plasma, as blood for the DPYD and UGT1A1 kits. Reagents are delivered in eight-well strips pre-loaded with a complete master mix in a dry format that is stable at room temperature. The tests have a turnaround time, including deparaffinization and lysis, of less than 3 hours, requiring less than 10 minutes of hands-on time. The Helix kit for cfDNA can be used with 1 to 5 ml of fresh or frozen plasma and has a turnaround time of less than 3 hours.

Read full article

Diatech Pharmacogenetics launches easyPGX, the ‘Ready to yoUSE’ CE-IVD Real-Time PCR line of products http://diatechpharmacogenetics.com/en/899/diatech-pharmacogenetics-launches-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/899/diatech-pharmacogenetics-launches-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products http://diatechpharmacogenetics.com/en/899/diatech-pharmacogenetics-launches-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products 11.04.2017 Jesi (AN), Italy, 07/04/2017: Diatech Pharmacogenetics srl., the leading Italian molecular diagnostic company today announces the launch of the easyPGX®, the ‘Ready to yoUSE’ CE-IVD Real-Time PCR line of products and of Helix®, a kit for the extraction of circulating free DNA (cfDNA) from plasma.

The easyPGX® product line includes kits for the detection of KRAS, NRAS, BRAF, EGFR, involved in many solid tumors, of DPYD and UGT1A1 variants associated with toxicity upon Fluoropyrimidines and Irinotecan treatment respectively, and a Thyroid panel. Each mix allows the co-amplification of one or more mutated alleles plus an endogenous control gene. A specific oligo control mix enables the evaluation of the quality and quantity of DNA in each sample. Positive and negative controls are included to allow the monitoring of the experimental workflow.
The sensitivity of the assays is as low as 0.5% and the starting material can be DNA extracted from fresh, frozen, formalin-fixed, paraffin-embedded (FFPE) tissues and plasma, and genomic DNA (gDNA) from whole blood for DPYD and UGT1A1.

easyPGX® products are:

  • ready to use, reagents are delivered in 8-well strips pre-loaded with a complete master-mix in a dry, stable at room temperature format.
  • easy to use, no need for freezing, thawing and the low number of pipetting steps minimizes the risk of errors. Each assay strips are color-coded.
  • fast to use, the turnaround time, including deparaffinization and lysis is less than 3 hours with less than 10 minutes hands-on time.
  • safe to use, it is manufactured under ISO13485 and designed, developed and validated in accordance with the Directive 98/79/EC on in vitro diagnostic medical devices. 

Helix®, circulating Nucleic Acid kit can be used from 1 to 5 ml of fresh or frozen plasma and the turnaround time is less than 3 hours.

For more information, please visit the product page.

Diatech launches at the AMP Congress easyPGX, the ‘Ready to yoUSE’ CE-IVD Real-Time PCR line of products http://diatechpharmacogenetics.com/en/900/diatech-launches-at-the-amp-congress-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/900/diatech-launches-at-the-amp-congress-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products http://diatechpharmacogenetics.com/en/900/diatech-launches-at-the-amp-congress-easypgx-the-‘ready-to-youse-ce-ivd-real-time-pcr-line-of-products 11.04.2017





For more info, please visit the product page.

Diatech Pharmacogenetics Bronze Sponsor at AMP Global 2017 http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 24.03.2017

Diatech Pharmacogenetics will be Bronze Sponsor at AMP GLOBAL 2017

Leonid EU opportunities Italian success - A revolutionary diagnostic device for lung cancer http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer 21.11.2016 PROGRAM

10:00 Welcome to Diatech!
Hall, 2° flor

11:00 Presentation of the results of the project LEONID
Auditorium, 2° flor

Welcome greetings

Fabio Biondi - Diatech Pharmacogenetics  President

Luca Ceriscioli - President of Regione Marche Mariangela Siler DG research and innovation in Health, Ministry of Health

11:30 Regional policies in the health field - Manuela Bora  Productive Activities of the Marche Region

11:50 Italian companies in European and national programs for R&I - Nicoletta Amodio Manager Research and Innovation, Confindustria

12:10 The history and the results of the project LEONID - Maura Menghi Scientific Director Diatech Pharmacogenetics

12:30 LEONID clinical study: presentation of preliminary results - Paola Ulivi Settore Biomarcatori e Medicina Personalizzata- Diagnostica molecolare III livello, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS Meldola

12:45 Myriapod® Lung Fusion Genes in the clinical practice  - Gabriella Fontanini Dipartimento di Patologia Medica Molecolare e di Area Critica, University of Pisa

13:00 Networking lunch, 2° flor




"Print-Age" An integrated approach for the promotion of health of old and fragile people: infections prevention, nutritional integration and personalized therapy http://diatechpharmacogenetics.com/en/904/print-age-an-integrated-approach-for-the-promotion-of-health-of-old-and-fragile-people-infections-prevention-nutritional-integration-and-personalized-therapy Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/904/print-age-an-integrated-approach-for-the-promotion-of-health-of-old-and-fragile-people-infections-prevention-nutritional-integration-and-personalized-therapy http://diatechpharmacogenetics.com/en/904/print-age-an-integrated-approach-for-the-promotion-of-health-of-old-and-fragile-people-infections-prevention-nutritional-integration-and-personalized-therapy 26.07.2016

Print-Age is a POR MARCHE FESR 2014-2020 funded project (Asse 1 – Obiettivo Specifico 3 – Azione 3.1: “Promuovere soluzioni innovative per affrontare le sfide delle comunità locali nell’ambito della salute e benessere” for a total budget of about  € 1,680,000  and a contribution of  € 847,889.63.

The project partnership includes companies and clinical investigators located in Marche Region. The following companies: Diatheva, Diatech Pharmacogenetics and Mivell, in order to exploit the scientific and industrial expertise in the field of diagnostics and nutraceutics, will create a synergy through an active collaboration with leading research centers, represented by the Università di Urbino “Carlo Bo” and the Università Politecnica delle Marche. The specific objective is to develop products that will be used through an integrated approach to improve the health of fragile and elderly people, optimizing, at the same time, public health expenditure.
Companies will also have the opportunity to test their products, in development, under real conditions (living labs). This will happen in private health care facilities for rehabilitation (Gruppo Santo Stefano, Porto Potenza Picena), in public health facilities for the care of older people” (Istituto Nazionale di Ricovero e Cura per Anziani, INRCA) and in structure for the acute management of fragile people (Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona).

Diatheva is the project leader and will coordinate all the research and experimentation activities concerning the development of:

• Diagnostic kit for personalized medicine;
• Diagnostic kits for the prevention of clinical risk in healthcare facilities;
• Nutraceuticals for vulnerable people.

The role of Diatech Pharmacogenetics concerns the development of a diagnostic kit to support  personalized treatments of vulnerable people. The research activity will be performed by using the MassARRAY technology and the validation for in vitro diagnostic use will be actuated following the 98/79/EC directive.
The final product will allow to analyze:

• Genetic polymorphisms that determine familiarity for cardiovascular diseases;
• Genetic polymorphisms predicting efficacy, toxicity and resistance to statins and likely predicting response to lipid-lowering nutraceuticals;
• Polymorphisms of genes involved into lipid metabolism, in inflammatory response and  antioxidant defense system.

The diagnostic and predictive value of the markers analyzed by the kit will be established in the clinical trials coordinated by INRCA.

Diatech and Inno-Train Diagnostik partecipate at the DGPhato congress http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress 19.05.2016 Diatech partecipate with Inno-Train Diagnostik our Germany distributor exclusive for the Easy line at the DGPhato Congress in Berlin from may 19th to 21st.
Come to visit us!

Diatech will be at States General Of Health Research http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research 26.04.2016 We will participate at the event "States General Of Health Research", on 27 and 28 April at the Auditorium Massimo, Rome.
For information visit the event website.
The speech of AD Oliva Alberti of Diatech Pharmacogenetics will be April 28 during "Health and Smart Technology. New tools for biomedical research: challenges and opportunities".
See the complete program.


Diatech will be at the Workshop and School on Cancer Development and Complexity http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity 23.04.2016 Diatech will partecipate at the "Lake Como Workshop and School  on Cancer Development and Complexity" May 24 – 27, 2016 – Villa del Grumello, Como, ITALY

Keynote Speakers

For more information visit the website .



Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment 27.10.2015 SAN DIEGO, Calif., Oct. 27, 2015 — Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics. The MassARRAY Dx PLUS assays improve upon existing methods on the market, enabling highly multiplexed screening of actionable targets in a single assay, thereby dramatically reducing cost and turnaround time for testing laboratories.

MassARRAY Dx PLUS assays will provide parallel analysis of the most frequently observed and actionable mutations in colon, lung, or melanoma tumors. Labs can rapidly test for the most critical mutations in KRAS, NRAS, BRAF, EGFR, and ALK genes to drive better patient treatment outcomes.

Clinical practice guidelines, such as those set forth by the European Society of Medical Oncology, necessitate screening mutations in oncogenes such as EGFR and/or KRAS for targeted treatment. As personalized treatment has evolved with the discovery of new biomarkers, as well as the advent of novel cancer drugs, such as tyrosine kinase inhibitors, the number of actionable mutations has expanded. However, the lack of a cost-effective, practical method for screening in parallel has complicated the ease of introducing new mutations into clinical testing.

For the compleate news plese go here.